NOVEL COMPOUNDS FOR TOMORROW'S CURES

THE SCIENCE

At Asha Therapeutics we are developing novel, first-in-class compounds targeting the point of greatest therapeutic impact for diseases with high unmet medical need. We have active programs in neuroscience for therapeutic intervention in neurodegenerative diseases including Parkinson's Disease (PD), Alzheimer's Disease (AD), and Amyotrophic Lateral Sclerosis (ALS), post-viral illnesses such as Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long Haul COVID, as well as Ischemic Stroke and Neuro-oncology.

Asha's Focus: The Big Four Neurological Diseases

THE
PRISM™ PLATFORM

Central to Asha's efforts to identify and drug difficult to hit targets with high disease relevance is our proprietary PRISM™ platform. PRISM™ is a novel physics-based drug design platform. 
image0.jpeg

LATEST NEWS

background_02.png

SUBSCRIBE TO NEWSLETTER

Thanks for subscribing!